Welcome to our dedicated page for C4 Therapeutics news (Ticker: CCCC), a resource for investors and traders seeking the latest updates and insights on C4 Therapeutics stock.
C4 Therapeutics, Inc. reports developments tied to its clinical-stage targeted protein degradation business, including oncology programs designed with its TORPEDO® platform. Recurring company updates cover cemsidomide, an oral IKZF1/3 degrader being studied in relapsed/refractory multiple myeloma, as well as broader degrader-medicine research intended to address disease-causing proteins.
Company news also includes collaboration activity, such as its Roche agreement for degrader-antibody conjugates, along with clinical disclosures, operating and financial results, conference participation, equity inducement grants, and other governance matters under Nasdaq rules.
C4 Therapeutics (Nasdaq: CCCC) has priced its upsized initial public offering at $19 per share, offering 9.6 million shares for gross proceeds of approximately $182.4 million. The offering is scheduled to begin trading on the Nasdaq Global Market on October 2, 2020, and is expected to close on October 6, 2020, pending customary closing conditions. The company has also granted underwriters a 30-day option to purchase an additional 1.44 million shares. C4T focuses on developing small-molecule drugs to selectively degrade disease-causing proteins for cancer and neurodegenerative conditions.